The utilisation of various nutritional items used as food or dietary supplements has expanded due to the surge in demand for HMOs. The availability of new technologies, such as enzymatic trans-glycosylation, which is used to artificially synthesise the HMOs, is one of the key reasons and market trends that propels the growth of the human milk oligosaccharides (HMO) market. The market for human milk oligosaccharides (HMO) is anticipated to generate significant revenue during the forecast period due to an expansion of its application potential in infant formula and functional foods and beverages, rapid technological advancement in the product line, an increase in consumer awareness of health issues, and the quick growth of the dairy industry.
The recession will have a significant effect on the market for human milk oligosaccharides. Consumers typically cut back on their purchases of speciality infant formulae that contain HMOs during a recession. This can result in less demand for HMOs and slower market expansion. Moreover, consumers may switch to less expensive infant formula products that do not contain HMOs in an effort to save money. This may result in a further decline in the market's demand for HMOs. Due to decreased manufacturing, transportation, and distribution, a recession may generate supply chain disruptions. This may alter the market's supply of HMOs, driving up costs and decreasing demand.
Alternative Animal Milk Oligosaccharides Are Starting To Appear, Which Will Help The Market Grow
The oligosaccharides included in cow's milk are anticipated to be crucial to baby nutrition. Infant formula made from goat milk is thought to have similar prebiotic qualities as breast milk and is anticipated to be important for a baby's digestive health, according to a laboratory study from RMIT University (Australia) that was published in the British Journal of Nutrition. Under the Kabrita brand, Ausnutria Nutrition BV (Netherlands) sells newborn formulae made with goat milk. Camel milk is another animal food source. A camel milk-based infant formula with a high iron content was introduced in 2018 by the Emirates Industry for Camel Milk and Products, popularly known as "Camelicious," a company based in the United Arab Emirates. Consequently, it is anticipated that these sources of animal milk oligosaccharides will become more popular in the markets for infant formula ingredients in the upcoming years. The manufacturing processes and the production environment are subject to strict regulatory standards in the environmental protection sector.
High Cost of Human Milk Oligosaccharides to Limit Market Growth
A significant aspect that would likely impede market expansion is the high cost of manufacture. Although the end result of chemical and enzyme synthesis in the creation of HMO is minimal, it still takes a lot of time and money. High-priced substrates, including glycosyl transferases, which demand enzyme production, are one of the key causes of HMOs' high cost. Prebiotics like fructooligosaccharides and galactooligosaccharides, which promote the health of newborns' gastrointestinal tracts by encouraging the growth of specific bacteria in the microbiota of the intestine, are used in infant formula to stop pathogenic Escherichia coli from developing. They are being used by manufacturers of infant formula as an alternative to HMOs because they are inexpensive and widely accessible. These functionally equivalent alternatives to HMOs as a result significantly restrict the market's ability to grow in terms of revenue.
Based on type, the human milk oligosaccharides market is segmented into 2’FL, 3’FL, 3’SL and 6’SL. The 2’FL category dominated the market in 2022 due to its well-known ability to protect against infectious diseases and by preventing toxins and pathogens from attaching to epithelial cells, 2'-fucosyllactose (2'FL) is a commonly used substance. Three different bifidobacterial species, including B. bifidum, B. dentium, and B. infantis, are responsible for the increase in 2'FL in the intestine.
Based on application, the human milk oligosaccharides market is segmented into infant formula, functional food & beverage and food supplements. The infant formula category dominated the market in 2022. Increased demand for HMOs in the design of newborn formulae as a result of HMOs' advantageous properties, including their ability to prevent infections, promote the growth of the brain and intestines, and increase memory and learning. Infant formula with HMO supplements is secure, well-tolerated, and encourages development in line with age. Human milk contains structurally diverse oligosaccharides that can improve the gastrointestinal and immune systems of breastfed infants.
By Distribution Channel
Based on distribution channel, the human milk oligosaccharides market is segmented into hypermarkets & supermarkets, drug store or pharmacy, mass merchandiser, departmental stores, mono-brand stores, specialty stores and online sales channel. The drug store or pharmacy category dominated the market in 2022. This is explained by the fact that pharmacy owners have prioritised convenience features like extended store hours and drive-through locations in order to draw in and keep customers in the face of growing competition from online retailers and supermarkets. The convenience of purchasing at neighbourhood pharmacies or drugstores is another factor that can encourage the growth of the market. Local pharmacies are often where people go to buy prescription drugs and other medical necessities like infant formula.
North America is projected to hold the largest share of the human milk oligosaccharides market over the forecast period due to the existence of important industry participants and the region's technological achievements. Health benefits of HMOs are one of the major drivers boosting market growth in the area as awareness among health-conscious consumers, mostly in the U.S., develops. The region's market revenue growth is anticipated to be fueled by an increase in the number of these customers, as well as by their growing awareness of and interest in functional meals and drinks with HMO enhancements. On the other hand, the Asia Pacific human milk oligosaccharides market is anticipated to grow significantly ascribed to elements like the region's growing population, mortality rate, disposable money, and consumer awareness of health and cleanliness. Due to the growing trend of health consciousness, Chinese consumers are embracing a healthy lifestyle. Some even spend their disposable income on functional and organic food and beverages.
LIST OF KEY COMPANIES PROFILED:
- Abbott Laboratories
- BASF S.E.
- Biosynth Carbosynth
- Chr. Hansen Holding A/S
- Dextra Laboratories Ltd.
- Dupont Nutrition & Biosciences
- Elicityl S.A.
- Glycom A/S
- Inbiose NV
- Medolac Laboratories
- Neolacta Lifesciences Pvt. Ltd
- Nestle Health Science
- Royal DSM
- In December 2019, 2' FL was given the all-clear by Food Standards Australia New Zealand (FSANZ) for optional use in infant formula products and specially prepared supplemental foods for young children. Escherichia coli K12 production strain SCR6 that has undergone genetic modification is used to create the approved 2' FL by microbial fermentation.
|Market Size in 2022||USD 194.5 Billion|
|Market Forecast in 2030||USD 800.6 Billion|
|Compound Annual Growth Rate||22.40 %|
|Unit||Revenue (USD Million) and Volume (Kilo Tons)|
|Segmentation||By Type, By Application, By Distribution Channel and By Geography|
|By Distribution Channel||